Pailleret Claire, Ait Hamou Zakaria, Rosencher Nadia, Samama Charles-Marc, Eyraud Violaine, Chilot François, Baillard Christophe
AP-HP, Hôpital Cochin, 27, rue du Faubourg-Saint-Jacques, 75014, Paris, France.
INSERM UMR_S1140, Faculté de Pharmacie, Paris, France.
Int Orthop. 2017 Sep;41(9):1839-1844. doi: 10.1007/s00264-017-3571-6. Epub 2017 Jul 25.
Managing hip fracture surgery in patients taking clopidogrel is challenging. The optimal timing for surgery remains unclear. Early surgery in such patients potentially increases peri-operative bleeding, whereas delayed surgery has been shown to be associated with worse postoperative outcomes. The aim of this study was to investigate whether a delay to surgery affects total blood loss, bleeding kinetics, blood transfusion requirements, or post-operative outcomes.
A retrospective monocentric study including all hip fracture patients treated with clopidogrel between 2011 and 2016 (39 patients) was carried out. Patients who underwent delayed surgery after withholding clopidogrel for five days or more, from 2011 to 2013, were compared to patients who benefited from earlier surgical procedures (within 48 hours of admission) from 2014 to 2016.
Total blood loss, amount of blood transfusion and rate of postoperative complications did not differ between the two groups. However, the timing of bleeding was significantly different; blood loss occurred during the pre-operative phase in the delayed surgery group (p < 0.0001), whereas it occurred during the intra-operative phase in the early surgery group (p = 0.005). The length of the hospital stay was significantly shorter for the early surgery group than for the delayed surgery group: 11 ± three versus 15 ± four days (p = 0.004).
Early surgical treatment of hip fracture in patients receiving clopidogrel does not increase the overall red blood cell loss or the transfusion requirement, but may affect the timing of blood transfusion. Hip fracture surgery should preferably be performed without delay in patients taking clopidogrel.
对服用氯吡格雷的患者进行髋部骨折手术管理具有挑战性。手术的最佳时机仍不明确。此类患者早期手术可能会增加围手术期出血,而延迟手术已被证明与更差的术后结果相关。本研究的目的是调查延迟手术是否会影响总失血量、出血动力学、输血需求或术后结果。
进行了一项回顾性单中心研究,纳入了2011年至2016年间接受氯吡格雷治疗的所有髋部骨折患者(39例)。将2011年至2013年停用氯吡格雷五天或更长时间后接受延迟手术的患者与2014年至2016年受益于早期手术(入院后48小时内)的患者进行比较。
两组之间的总失血量、输血量和术后并发症发生率没有差异。然而,出血时间有显著差异;延迟手术组的失血发生在术前阶段(p < 0.0001),而早期手术组的失血发生在术中阶段(p = 0.005)。早期手术组的住院时间明显短于延迟手术组:11 ± 3天对15 ± 4天(p = 0.004)。
接受氯吡格雷治疗的患者早期进行髋部骨折手术不会增加总体红细胞丢失或输血需求,但可能会影响输血时间。服用氯吡格雷的患者最好不要延迟进行髋部骨折手术。